SEC Filings
Coherus Says Tagmokitug Produced Responses In 6 Of 8 First-Line Esophageal Cancer Patients
The experimental antibody, paired with toripalimab and chemotherapy, showed a 75% confirmed response rate in a small interim cohort.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
The experimental antibody, paired with toripalimab and chemotherapy, showed a 75% confirmed response rate in a small interim cohort.
Earnings
Buybacks and a lower tax rate drive the higher forecast, while third-quarter sales slipped about 2.9% to $3,487 million.
SEC Filings
Vanda also lost its HETLIOZ patent suits in Delaware and set a November 2027 generic entry date for Fanapt, its 10-Q shows.
Earnings
Nine-month operating cash flow fell to $115.1 million while PROPWR equipment commitments climbed, even as third-quarter profit returned.
Earnings
The brewer's third-quarter revenue rose 4.9% organically, while volumes in China fell 16.8%.
SEC Filings
The seller note ran above the $320.0 million to $340.0 million range PBF gave in July, as the refiner retired $1.3 billion of notes.
SEC Filings
The cash floor on Phathom's royalty financing rose from $30 million on October 1, while generic-drug filers challenge its exclusivity.
SEC Filings
Nothing was borrowed at September 30, and the loan matures in December 2029, as export cigarettes made for others climb.
SEC Filings
The printer maker lowered its 2026 profit and cash-flow forecasts even as its adjusted operating margin rose to 6.6% from 3.3%.
SEC Filings
Operating cash rose to $670.5 million for nine months, but capital spending jumped to $812.0 million, leaving less free cash than a year ago.
Earnings
Adjusted earnings rose 15% to $2.26 a share, and Belden signed a $100 million fiber supply deal with a US data center customer for 2027.
Earnings
Third-quarter net income rose 7% to $317 million as revenue slipped slightly and self-pay subscribers edged up by about 5,000.